

## The complex liver cancer patient has been shown to benefit from TriNav's Pressure-Enabled Drug Delivery™ (PEDD™) approach

A recently published, comprehensive Real-World Evidence (RWE) study analyzed TACE and TARE claims between 2019 and 2022 using a database containing more than 300 million patient records. ***The study showed that IRs choose the TriNav Infusion System over a traditional microcatheter to treat their most challenging patients - those with higher disease burden and/or reduced liver function.***<sup>1</sup>

For these complex patients, optimizing the T:N ratio is an important therapeutic goal.



TriNav's PEDD approach increases therapeutic delivery to the tumor,<sup>2</sup> while simultaneously decreasing non-target delivery.<sup>3</sup> [Learn more about the real-world and clinical evidence that supports the use of TriNav in TARE and TACE.](#)

**You can also check-out the case presentations which highlight how Interventional Radiologists are successfully using TriNav to treat their complex patients.**

[Click Here to View Case Presentations](#)

### Indications

For Use The TriNav Infusion System is intended for use in angiographic procedures. It delivers radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.<sup>4</sup>

### Contraindications

TriNav is not intended for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).

Rx Only. For the safe and proper use of the TriNav Infusion System, refer to the Instructions for Use.

### References

1. Keziah Cook, Deepshikhar Gupta, Yunjuan Liu, Chris Miller-Rosales, Fangzhou Wei, Edward Tuttle, Steven C. Katz, Richard Marshak & Alexander Y. Kim (2024) Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases, *Current Medical Research and Opinion*, 40:4, 591-598, DOI: 10.1080/03007995.2024.2322057
2. Titano, J. J. et al. End-hole Versus Microvalve Infusion Catheters in Patients Undergoing Drug-Eluting Microspheres-TACE for Solitary Hepatocellular Carcinoma Tumors: A Retrospective Analysis. *Cardiovasc. Intervent. Radiol.* 42, 560–568 (2019).
3. Pasciak, A. S., McElmurray, J. H., Bourgeois, A. C., Heidel, R. E. & Bradley, Y. C. The impact of an antireflux catheter on target volume particulate distribution in liver-directed embolotherapy: a pilot study. *J. Vasc. Interv. Radiol.* JVIR 26, 660–669 (2015).
4. TriSalus™ TriNav® Infusion System, Instructions for Use